Active Biotech AB (publ) announced that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer, effective January 1, 2022. He will join the executive management team and be responsible for the development of the company´s clinical project portfolio within solid and hematological cancers, and inflammatory eye disorders.